A case report shows that semaglutide can trigger small bowel obstruction in patients with a history of gastrointestinal motility issues, highlighting the need for careful patient screening.
1 case of bowel obstructionA 55-year-old woman with prior GI issues developed small bowel obstruction after starting semaglutide, resolved with conservative treatment
What the researchers found
A 55-year-old woman with obesity, type 2 diabetes, and a prior history of small bowel obstruction developed severe abdominal pain and was diagnosed with small bowel obstruction after initiating semaglutide therapy. The obstruction was attributed to the drug's mechanism of slowing gastric emptying and altering the migrating motor complex, compounded by her preexisting GI vulnerability.
The patient was treated conservatively with nasogastric decompression and bowel rest, and her condition resolved. However, the case prompted reassessment of continued GLP-1 RA therapy, underscoring that the benefits of glycemic control must be weighed against GI risks in susceptible individuals.
Why it matters
GLP-1 receptor agonists are among the most prescribed medications worldwide for diabetes and weight loss. As their use expands rapidly, understanding rare but serious side effects like bowel obstruction is critical — especially for patients with prior GI issues who may be at elevated risk. This case reinforces the importance of personalized prescribing decisions.
How the study worked
This was a single-patient case report combined with a literature review. The authors documented the clinical presentation, diagnosis, and treatment of a patient who developed bowel obstruction after starting semaglutide, then reviewed existing evidence on GLP-1 receptor agonist-associated gastrointestinal complications.
What this study cannot tell us
As a single case report, this study cannot establish causation or quantify how common bowel obstruction is among GLP-1 RA users. The patient had a preexisting history of bowel obstruction, making it difficult to determine how much the medication versus her underlying condition contributed. Larger epidemiological studies are needed to assess the true incidence of this complication.
How to read the evidence
This is a single case report with a literature review, representing one of the lowest levels of clinical evidence. While valuable for raising awareness of a potential adverse effect, it cannot establish frequency or causation.
When this study was published
Published in 2025, this is a very recent case report reflecting current prescribing patterns with semaglutide and other GLP-1 receptor agonists.
The bigger picture
The explosive growth of GLP-1 receptor agonist prescriptions for both diabetes and obesity means more patients with complex medical histories are being exposed to these drugs. Reports like this help build the safety profile of semaglutide and related medications, informing clinical guidelines about which patients may need closer monitoring or alternative therapies.
Questions still open
- How common is bowel obstruction among GLP-1 receptor agonist users with prior GI motility issues compared to those without?
- Are certain GLP-1 receptor agonists less likely to cause severe GI complications than others?
- What screening protocols could help identify patients at highest risk before starting GLP-1 therapy?
Common questions
Can GLP-1 drugs like semaglutide cause bowel obstruction?
Should people with GI issues avoid GLP-1 receptor agonists?
Read the original research
GLP-1 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management.
Cureus, 17(4), e81891
Citation
Jones, Matthew; Cappola, James J. (2025). GLP-1 Receptor Agonists in Diabetes and Obesity: A Case Report and Review of Bowel Obstruction Risks and Management.. Cureus, 17(4), e81891. https://doi.org/10.7759/cureus.81891